Is Norditropin the Most Common Growth Hormone?
No, Norditropin is not the most common growth hormone. Somatropin (recombinant human growth hormone, or rhGH) is prescribed under multiple brand names, with Norditropin (made by Novo Nordisk) ranking among the top but not the leader in U.S. market share or prescriptions. In 2023, it held about 25-30% of the U.S. rhGH market, behind competitors like Genotropin (Pfizer) and Humatrope (Eli Lilly).[1][2]
What Are the Top Prescribed Growth Hormones?
U.S. prescription data from IQVIA shows these as the leaders by volume and revenue (2023 estimates):
- Genotropin (Pfizer): Around 35% market share; most prescribed due to long market presence and pediatric formulations.
- Norditropin (Novo Nordisk): 25-30%; popular for its FlexPro pen device and once-weekly option (Ngenla variant).
- Humatrope (Eli Lilly): 15-20%; favored in some adult GH deficiency cases.
- Omnitrope (Sandoz): 10%; a biosimilar gaining traction for lower cost.
Nutropin (Genentech) and Saizen (Merck) trail with under 10% each. Globally, patterns are similar, though Omnitrope leads in Europe due to biosimilar adoption.[1][3]
Why Isn't Norditropin #1?
Genotropin dominates U.S. pediatric use (80% of GH prescriptions), where growth hormone is most needed for conditions like GH deficiency or Turner syndrome. Norditropin excels in ease-of-use (needle-free pens) but faces competition from Genotropin's established guidelines and insurance preferences. Market shifts favor biosimilars like Omnitrope, eroding brand shares.[2][4]
How Do Prescription Trends Look Over Time?
rhGH prescriptions grew 5-7% annually pre-2023, driven by expanded approvals (e.g., Prader-Willi syndrome). Post-2020, biosimilars cut costs 20-30%, boosting volumes but pressuring brands. Norditropin's share dipped from 32% in 2019 to 27% in 2023 as Ngenla (weekly dosing) launched but hasn't displaced dailies yet.[3]
When Do Key Patents Expire?
Norditropin's core U.S. patents (e.g., device and formulation) expired around 2020-2022, enabling biosimilars. Genotropin patents lapsed earlier (2015-2018), accelerating competition. Check DrugPatentWatch.com for latest litigation: Norditropin patents.[5]
What Do Patients Report on Side Effects and Choices?
Common complaints across brands include injection-site reactions (20-30% of users), headaches, and joint pain. Norditropin users praise its pen (less intimidating for kids), but Genotropin wins on reliability in forums like Drugs.com reviews. Cost-sharing varies: branded pens run $1,000-2,000/month pre-insurance, biosimilars $500-1,000.[4][6]
Sources
[1]: IQVIA National Prescription Audit, 2023
[2]: Evaluate Pharma World Preview 2024
[3]: Novo Nordisk Annual Report 2023
[4]: Drugs.com user reviews (aggregated 2024)
[5]: DrugPatentWatch.com - Norditropin
[6]: GoodRx pricing data, 2024